JUL 19, 2016 7:51 AM PDT

CAR-T Cells that Kill Cancer Now Kill HIV Too

WRITTEN BY: Xuan Pham
A decade-old technology to arm the immune system to fight cancer is now being adapted to fight HIV, one of the most pernicious viruses in human history. The premise of this immunotherapy rests on chimeric antigen receptor (CAR) T cells that are now mobilized to destroy HIV.

Technique to boost immune system to fight cancer can also fight HIV | Image: NIAID/Flickr
 
Immunotherapy is a relatively new and attractive line of treatment that stimulates the body’s natural defenses to kill foreign invader cells. Most prominently, this technology has been successfully adapted to target and destroy some cancer types.
 
In particular, one type of cancer immunotherapy involves the genetically modification of the patient’s immune T-cells to carry a synthetic receptor molecule called a CAR (for chimeric antigen receptor). These specialized CAR-T cells are then able to recognize and destroy cancer cells that have a specific marker, known as CD19.
 
Because CAR-T cells have been effective at boosting the patient’s own immune system to fight cancer, researchers have wondered whether this technology can be adapted to fight HIV. Indeed, such experiments were carried out in the early 1990s, but were soon halted due to the lack of effectiveness in clinical trials. However, the promise of CAR-T immunotherapy prevailed, and prompted a fresh start by scientists at the UCLA AIDS Institute and Center for AIDS Research.
 
Fortunately this time, CAR-T cells appear to be a new powerful weapon against HIV. The secret to their success? UCLA researchers had access to new antibodies that were only discovered in the past few years.
 
Specifically, the team had seven antibodies that were classified as “broadly neutralizing antibodies,” meaning these proteins can bind to many types of viruses. Then, researchers exploited this capability by making CAR-T cells with receptors against a number of HIV strains.
 

 "We took new generation antibodies and engineered them as artificial T-cell receptors, to reprogram killer T cells to kill HIV-infected cells," said Otto Yang, a professor at the School of Medicine at UCLA, and director of vaccine and pathogenesis research at the AIDS Institute and Center for AIDS Research. "Others have used antibodies against cancer antigens to make artificial T-cell receptors against cancer and shown this to be helpful in cancer treatment."
 
In the lab, this translated to killer T cells that can multiply, and then target HIV-infected cells for destruction. And while the immune system can do this naturally, the onslaught of HIV infection overwhelms the body’s responses. Having CAR-T cells would boost this reaction, such that the immune system can overcome HIV.
 
While this is the first success of immunotherapy against HIV in 15 years, the research team is proceeding cautiously. "What works in a test tube doesn't necessarily work in a person, so the next step is to find strategies to put these receptors into humans. But this therapy shows enough promise to move forward with further research," said Yang.

Additional sources: UCLA press release
About the Author
I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
AUG 24, 2022
Immunology
Immune Cells Can Use 'Waste' as a Powerful Fuel
AUG 24, 2022
Immune Cells Can Use 'Waste' as a Powerful Fuel
T cells are on the front lines of the immune system, monitoring the body for pathogens, and springing into action when t ...
SEP 11, 2022
Microbiology
Using Yeast Cells to Make a Cancer Treatment
SEP 11, 2022
Using Yeast Cells to Make a Cancer Treatment
Vinblastine and vincristine are both common chemotherapies that are used to treat several types of cancer. The drugs sto ...
SEP 13, 2022
Cancer
Emerging Drug Targets in Cancer Immunotherapy
SEP 13, 2022
Emerging Drug Targets in Cancer Immunotherapy
Introduction Cancer is the second leading cause of death globally. According to estimates from the American Cancer Socie ...
SEP 28, 2022
Drug Discovery & Development
Impact of In Vivo Controls on Therapeutic Drug Development
SEP 28, 2022
Impact of In Vivo Controls on Therapeutic Drug Development
The significance of antibody based in vivo studies   For both research and therapeutic purposes, antibodies ca ...
OCT 12, 2022
Plants & Animals
Mediterranean Diet Improves Immunotherapy Response in Advanced Melanoma Patients
OCT 12, 2022
Mediterranean Diet Improves Immunotherapy Response in Advanced Melanoma Patients
The Mediterranean diet has been popularized in recent years for its wide-ranging health benefits. Among the many health ...
NOV 02, 2022
Clinical & Molecular DX
New Genetic Variants Identified as Risk Factors for Ovarian Cancer
NOV 02, 2022
New Genetic Variants Identified as Risk Factors for Ovarian Cancer
Ovarian cancer is a complex disease resulting from mutated cells in the ovaries. As the cells multiply, they can invade ...
Loading Comments...